Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H20F2N4O4 |
| Molecular Weight | 430.4047 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](NC(=O)[C@@H](O)C1=CC(F)=CC(F)=C1)C(=O)N[C@H]2C3=CC=CC=C3C=NN(C)C2=O
InChI
InChIKey=HXEHCCYOTHDPPI-NBHSMZAVSA-N
InChI=1S/C21H20F2N4O4/c1-11(25-20(30)18(28)13-7-14(22)9-15(23)8-13)19(29)26-17-16-6-4-3-5-12(16)10-24-27(2)21(17)31/h3-11,17-18,28H,1-2H3,(H,25,30)(H,26,29)/t11-,17-,18-/m0/s1
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Signal peptide peptidase and gamma-secretase share equivalent inhibitor binding pharmacology. | 2007-12-21 |
|
| Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice. | 2007-10 |
|
| Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease. | 2007-07-15 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23656215
Created by
admin on Mon Mar 31 22:38:22 GMT 2025 , Edited by admin on Mon Mar 31 22:38:22 GMT 2025
|
PRIMARY | |||
|
R1E8M783K2
Created by
admin on Mon Mar 31 22:38:22 GMT 2025 , Edited by admin on Mon Mar 31 22:38:22 GMT 2025
|
PRIMARY | |||
|
935525-13-6
Created by
admin on Mon Mar 31 22:38:22 GMT 2025 , Edited by admin on Mon Mar 31 22:38:22 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
